MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced that data from the Phase III clinical trial evaluating toremifene 80 mg for the treatment of estrogen deficiency side effects of androgen deprivation therapy will be presented this evening in a moderated poster session at the Fourth Annual Chicago Supportive Oncology Conference.
